This Article Full Text (PDF) All Versions of this Article: 1087054707308490v1 11/6/720    most recent References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Adler, L. A. Articles by Biederman, J. Search for Related Content PubMed PubMed Citation Articles by Adler, L. A. Articles by Biederman, J. Pubmed/NCBI databases Medline Plus Health Information Attention Deficit Hyperactivity Disorder Social Bookmarking                         What's this?

Functional Outcomes in the Treatment of Adults With ADHD

New York University School of Medicine, Lenard.adler{at}med.nyu.edu

Thomas J. Spencer

Massachusetts General Hospital and Harvard Medical School

Louise R. Levine

Lilly Research Laboratories

Janet L. Ramsey

Lilly Research Laboratories

Roy Tamura

Lilly Research Laboratories

Douglas Kelsey

Lilly Research Laboratories

Susan G. Ball

Lilly Research Laboratories

Albert J. Allen

Lilly Research Laboratories

Joseph Biederman

Massachusetts General Hospital and Harvard Medical School

Objective: ADHD is associated with significant functional impairment in adults. The present study examined functional outcomes following 6-month double-blind treatment with either atomoxetine or placebo. Method: Patients were 410 adults (58.5% male) with DSM-IV—defined ADHD. They were randomly assigned to receive either atomoxetine 40 mg/day to 80 mg/day (n = 271) or placebo (n = 139). The primary functional outcome measure was the Endicott Work Productivity Scale (EWPS), and the secondary measure was the Adult ADHD Quality of Life (AAQoL). Patients were seen for four visits in 6 months. Results: At 6 months, both groups had nonsignificantly different improvements in EWPS total scores. Atomoxetine-treated patients showed significantly greater improvement than placebo-treated patients on the AAQoL after controlling for baseline severity of ADHD. Both treatment groups had low 6-month study completion rates. Conclusion: Following 6-month treatment with atomoxetine, adults with ADHD showed significantly greater improvement in functioning on disease-specific measures of quality of life than patients treated with placebo. (J. of Att. Dis. 2008; 11(6) 720-727)

Key Words: ADHD • functional outcomes • atomoxetine • AAQoL • EWPS • long-term

This version was published on May 1, 2008

Journal of Attention Disorders, Vol. 11, No. 6, 720-727 (2008)
DOI: 10.1177/1087054707308490


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?